## John D Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7169936/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet. Neural Regeneration Research, 2022, 17, 1975.	3.0	8
2	In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. ACS Pharmacology and Translational Science, 2022, 5, 41-51.	4.9	5
3	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages. Journal of Immunology, 2022, 208, 133-142.	0.8	1
4	A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. Journal of Neurochemistry, 2021, 158, 807-817.	3.9	12
5	TDP-43 Puts the STING in ALS. Trends in Neurosciences, 2021, 44, 81-82.	8.6	14
6	Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2021, 63, 108-113.	2.2	2
7	Complement: a global immunometabolic regulator in amyotrophic lateral sclerosis. Neural Regeneration Research, 2021, 16, 1210.	3.0	5
8	Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. Amino Acids, 2021, 53, 143-147.	2.7	12
9	Glucose clearance and uptake is increased in the SOD1 <sup>G93A</sup> mouse model of amyotrophic lateral sclerosis through an insulinâ€independent mechanism. FASEB Journal, 2021, 35, e21707.	0.5	9
10	Complement peptide receptors in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	1
11	Intrinsic bias at non-canonical, Î <sup>2</sup> -arrestin-coupled seven transmembrane receptors. Molecular Cell, 2021, 81, 4605-4621.e11.	9.7	69
12	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein oupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
13	The emerging role of complement in neuromuscular disorders. Seminars in Immunopathology, 2021, 43, 817-828.	6.1	9
14	Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 2021, 64, 16598-16608.	6.4	8
15	Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays <i>In Vitro</i> and <i>In Vivo</i> . ACS Pharmacology and Translational Science, 2021, 4, 1808-1817.	4.9	4
16	The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia, 2020, 68, 407-421.	4.9	133
17	Is the C3a receptor antagonist SB290157 a useful pharmacological tool?. British Journal of Pharmacology, 2020, 177, 5677-5678.	5.4	3
18	Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration. Journal of Immunology, 2020, 205, 2834-2839.	0.8	17

John D Lee

#	Article	IF	CITATIONS
19	Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. Biochemical Pharmacology, 2020, 180, 114156.	4.4	47
20	Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2020, 57, 4143-4155.	4.0	21
21	The Peripheral Immune System and Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2020, 11, 279.	2.4	57
22	Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. ACS Omega, 2020, 5, 2345-2354.	3.5	64
23	The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. FASEB Journal, 2020, 34, 7225-7233.	0.5	8
24	The "C3aR Antagonist―SB290157 is a Partial C5aR2 Agonist. Frontiers in Pharmacology, 2020, 11, 591398.	3.5	11
25	Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
26	C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma. FASEB Journal, 2019, 33, 11060-11071.	0.5	23
27	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
28	The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity. Journal of Immunology, 2019, 202, 3339-3348.	0.8	97
29	Gut microbiota in ALS: possible role in pathogenesis?. Expert Review of Neurotherapeutics, 2019, 19, 785-805.	2.8	30
30	Revisiting the role of the innate immune complement system in ALS. Neurobiology of Disease, 2019, 127, 223-232.	4.4	35
31	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2019, 16, 45.	7.2	21
32	Complement dysregulation in the central nervous system during development and disease. Seminars in Immunology, 2019, 45, 101340.	5.6	85
33	Complement peptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
34	Defects in synaptic transmission at the neuromuscular junction precede motor deficits in a TDPâ€43 <sup>Q331K</sup> transgenic mouse model of amyotrophic lateral sclerosis. FASEB Journal, 2018, 32, 2676-2689.	0.5	52
35	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Scientific Reports, 2018, 8, 8101.	3.3	21
36	Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. Molecular Immunology, 2018, 101, 176-181.	2.2	30

John D Lee

#	Article	IF	CITATIONS
37	Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2018, 15, 171.	7.2	45
38	Pharmacological inhibition of complement C5a 5a <sub>1</sub> receptor signalling ameliorates disease pathology in the hSOD1 <sup>G93A</sup> mouse model of amyotrophic lateral sclerosis. British Journal of Pharmacology, 2017, 174, 689-699.	5.4	79
39	Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCI¶. Journal of Neuroscience, 2017, 37, 5395-5407.	3.6	63
40	Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1C93A mouse model of amyotrophic lateral sclerosis. Skeletal Muscle, 2017, 7, 10.	4.2	45
41	Noninvasive assessment of altered activity following restraint in mice using an automated physiological monitoring system. Stress, 2017, 20, 76-84.	1.8	6
42	Motor neuron disease proteins activate complement and generate C5a. Molecular Immunology, 2017, 89, 168.	2.2	0
43	Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. Scientific Reports, 2016, 6, 37968.	3.3	85
44	Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Seminars in Immunology, 2016, 28, 292-308.	5.6	66
45	A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. Immunobiology, 2016, 221, 1209.	1.9	2
46	Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2015, 12, 90.	7.2	69
47	Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3-4.	7.1	45
48	Dysregulation of the complement cascade in the hSOD1G93Atransgenic mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2013, 10, 119.	7.2	76
49	Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E305-E313.	3.5	14
50	Impairments to the GH-IGF-I Axis in hSOD1G93A Mice Give Insight into Possible Mechanisms of GH Dysregulation in Patients with Amyotrophic Lateral Sclerosis. Endocrinology, 2012, 153, 3735-3746.	2.8	21
51	The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres. Journal of Neuroinflammation, 2009, 6, 34.	7.2	17